Cardiol Therapeutics (TSX:CRDL), (NASDAQ:CRDL) is a biotechnology company focused on researching and developing innovative cannabidiol (CBD) treatments for heart diseases and other medical conditions. With a commitment to scientific excellence, Cardiol's projects include the development of anti-inflammatory therapies aimed at reducing the risk of cardiovascular diseases and improving patient outcomes. The company's objectives center around leveraging their proprietary technologies and pharmaceutical expertise to lead the way in developing safer, more effective CBD-based medicines. Cardiol Therapeutics Class A is also traded on the Nasdaq under the ticker code (NASDAQ:CRDL), enabling a broader international investment base to support its mission in transforming cardiovascular treatment landscapes.